Ocular Therapeutix and Eyepoint Pharmaceuticals are developing competing eye treatments. The competition between them becomes tense. The tension comes on the eve of a key reading of results from the pivotal Ocular Therapeutix eye treatment study. Eyepoint Pharmaceuticals goes after Ocular Therapeutix as a rival. Ocular Therapeutix screened the first three subjects in the Phase 3 SOL-1 clinical trial for AXPAXLI in February.[5] Eyepoint Pharmaceuticals is testing EYP-1901, a pan-VEGF receptor inhibitor, in the DAVIO-2 trial against aflibercept after three loading doses 8 weeks apart.[5] Both companies operate in the field of ophthalmology with the potential for long-term study results.